Slides
Page 1
Rapid Micro Biosystems Sidoti Small-Cap ConferenceSeptember 24, 2026 R A P I D M I C R O B I O S Y S T E M S N A S D A Q : R P I D© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 2
Rapid Micro Biosystems Disclaimers 2 This presentation has been prepared by Rapid Micro Biosystems, Inc. (the “Company”) solely for informational purposes. This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, sales of the Company's products, including placements of Growth Direct systems, and their impact on the Company’s revenue; goals with respect to continued improvement in gross margins and cash management; and the Company’s distribution and collaboration agreement and the terms thereof, including future collaboration opportunities between the parties; the benefits and features of the Company's products and technology; the Company's expectations as to the market for its products, including with respect to market size and product adoption; the Company's goal and pathway to achieve cashflow breakeven; the Company's revenue and gross margin targets, including the anticipated drivers thereof; and the Company's efforts to drive sustainable, long-term growth and shareholder value. In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to the Company’s significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations and guidance about its business and operations; the effectiveness of the Company’s sales and marketing efforts; the Company’s ability to sell and place its products with customers; the Company’s ability to develop new products and adapt to technological change; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; competition within the Company’s industry; the size of the total addressable market for the Company's products and purchasing patterns and practices within its target customer base; the Company’s ability to maintain its manufacturing operations; the Company’s efforts to improve gross margins for its products; the Company's ability to manage costs in operating its business; the Company’s ability to maintain and grow its relationships with its collaborators, including MilliporeSigma; the Company’s ability to manage its collaboration with MilliporeSigma and to realize the intended benefits of the distribution and collaboration agreement; the impact of the terms of the distribution and collaboration agreement on the Company’s business and results of operations; the Company’s ability to negotiate and enter into future collaboration opportunities and to realize the intended benefits therefrom; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility on the Company’s business and operations; and the other important factors outlined under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 12, 2026, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this presentation to reflect changes since the date of this presentation, except as may be required by law.This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful. You agree to keep any information provided herein confidential and not to disclose any of the information to any other parties without prior express written permission of the Company. Neither the information contained in this presentation nor any further information made available by the Company or any of its affiliates or employees, directors, representatives, officers, agents or advisers in connection with this presentation will form the basis of, or be construed as, a contract or any other legal obligation.© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 3
Rapid Micro BiosystemsThe standard in automating microbial quality control320%Year / Year Growth$34MTotal Revenue2 0 2 5 R E V E N U EG L O B AL S Y S T E M S(1)C U S T O M E R S$18MRecurring Revenue169Cumulative Validations200Cumulative Placements~20Countries86%Approved CAR-T Manufacturers75%Top 20 Global Pharma (2) Rapid Micro Biosystems(1) As of June 30, 2026(2) By revenue© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 4
Rapid Micro BiosystemsA focused, scalable growth strategy built to deliver sustainable, long-term shareholder value Strategically well positioned for growth and margin expansion 4© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. • Strong business fundamentals with 200 systems placed globally and >50% recurring revenue• Expanding enterprise deployments and multi-system opportunities with leading global biopharma customers• Recurring revenue powered by increasing demand for consumables and services for growing installed base• Gross margin inflection underway with continued expansion expected through 2027 and beyond• MilliporeSigma expected to drive meaningful placement growth, gross margin expansion and innovation• Positioned to capitalize on automation, digitalization, reshoring and biomanufacturing growth trends• Disciplined approach to growth and profitability with declining cash usage; executing toward positive cash flow by year-end 2028 • Actively evaluating opportunities to strengthen balance sheet and maximize shareholder value
Page 5
Rapid Micro Biosystems COur visionWe are transforming a critical, regulated part of the global pharmaceutical manufacturing process, bringing microbial quality control into the 21st century.The new standard in microbial quality controlRapid Micro Biosystems5© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 6
Rapid Micro Biosystems Scientific and technology innovationGrowing demand for more complex therapiesFaster & leanermanufacturingData integrity & security focusRegulatoryscrutiny+F A C T O R S D R I V I N G C H A N G EDiscovery & researchQuality control (QC) & AnalysisBioprocessing & manufacturing T O D A YT O D A YT O D A YT O D A Y T O D A YT O D A YFlexible single use technologiesHigh-throughput R&D automation Microbial quality control (MQC) has not kept up with pharma industry innovation+++ 6Rapid Micro Biosystems© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 7
Rapid Micro Biosystems Insecure and lacking data integrityHigh volume testing mandated by regulatorsManual, paper-basedand slowSubjective andprone to human error7 Challengesin a traditional MQC lab © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 8
Rapid Micro Biosystems THE GROWTH DIRECT®(GD) PLATFORM The only fully automated,high-throughput and secure MQC solution…Proprietary Consumables Data & Software Global Validation & Support Services …designed to deliver a compelling value proposition Data IntegritySupports global quality regulatory compliance and improved data handling and management Operational EfficiencyEnablesfaster decision making by accelerating time to results by 50% or faster compared to the traditional method Insight & AccuracySubstantially reduce human quality control errors and the risk of costly recalls and regulatory interventions8 Modernizing MQC with the Growth Direct®platform © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 9
Rapid Micro Biosystems Growth Direct®automates all MQC tests in pharma manufacturing 9© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. For Environmental Monitoring• Tryptic Soy Agar (TSA) with Lecithin• TSA with LP80HT (histidine and thiosulphate)For Bioburden Testing• Sabouraud Dextrose Agar (SDA) for yeasts and molds • Tryptic Soy Agar (TSA) for general product testingFor Water Testing• R2 Agar (R2A) For Sterility Testing• Rapid Sterility Media (RSM) The only fully automated non-destructive growth-based technology impacting mission-critical microbial QC testing applications
Page 10
Rapid Micro Biosystems P U L L Q C TE S T F O R M1.F IL L O U TA S S A Y IN F O2.P R E P A R ES A MP L E S3.L O A DIN C U B A TO R4.P U L LS A MP L E S5.P E R F O R MC O U N TS6.R E C O R DC O U N TS7.R E TU R NS A MP L E S8.S H IF TS A MP L E S9.P U L LS A MP L E S10.P E R F O R MC O U N TS11.D IS C A R D15.K E YIN TO L IMS14.P E R F O R MD U A L - R E AD 12.R E C O R DC O U N TS13.R E S U L TS Prepare sample & automated loading1 Automated incubation and analysis & data handling2 Results Manual & subject to error15 steps5-14 days to result / testUnsecured Automated & accurate2 stepsResults in half the timeFull data integrity 10 Growth Direct®modernizes MQCM A N U A L W O R K F L O WG R O W T H D I R E C T®A U T O M A T E D W O R K F L O WRapid Micro Biosystems© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 11
Rapid Micro Biosystems The Growth Direct®System brings MQC into the 21st Century Discovery & researchQC & AnalysisBioprocessing & manufacturing T O D A YT O D A YT O D A Y 11 Scientific and technology innovationGrowing demand for more complex therapiesFaster & leanermanufacturingData integrity & security focusRegulatoryscrutiny+F A C T O R S D R I V I N G C H A N G E+++ © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.Flexible single use technologiesHigh-throughput R&D automation
Page 12
Rapid Micro Biosystems Market forces pushing pharma industry to automation 12Sources: FDA, EvaluatePharma, Alliance for Regen. Medicine © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.RegulatoryPressureIncreasing regulatory scrutiny and enforcement around data integrity and qualityIndustryChangeGrowth in complex biologics and cell & gene therapies which require faster, more accurate, higher throughput testing capabilitiesLarge andGrowing Market$5B annual recurring revenue + $5B global system opportunityExpanding Manufacturing Capacity, Especially U.S. ReshoringIncreasing investments in new manufacturing capacity create significant opportunity for automation
Page 13
Rapid Micro Biosystems Land and expand growth strategy augmented by innovation 13 P U R S U E A D J A C E N TM A R K E T SD R I V E E N T E R P R I S ED E P L O Y M E N T SE X P A N D I N T ON E W G E O G R AP H I E SL A U N C H N E W P R O D U C T SAN D S E R V I C E SG R O W N E WC U S T O M E R AD O P T I O NB IOP HA R MA(in c l. c e ll& g e n e )CD MO S TE RIL EINJ E C TA B L E ,V A CC INE ,& O THE R LAND AND EXPAND STRATEGY Sampleautomation Additional test types(e.g. sterility) AI & cloud-driven data services Automatedmicrobial ID CoreGrowth DirectCapabilities EM + W/BB + Sterility +EM + W/BB + Sterility +EM + W/BB + Sterility +Site1Site2Site3+© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 14
Rapid Micro Biosystems 14 C U S T O M E R S E G M E N T S W I T H E S T A B L I S H E D U S EG L O B A L S I T E S W I T H G R O W T H D I R E C T S Y S T E M Sof approved CAR-T manufacturers have GD system placed86%cumulativesystems validated169cumulative consumables sold9M+customer manufacturing sites100+cumulativesystems placed200of top 20global pharmaare customers75%G R O W T H D I R E C T AP P L I C A T I O N SEnvironmentalMonitoringWaterTestingBioburdenTestingRapid SterilityTestingRapid Micro Biosystems BiologicsSmall MoleculesCDMOPersonal Care ProductsCell & Gene Therapy / CAR-T Customer base includes 75% of the top 20 global pharma companies1with significant growth potential © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.1 By revenue
Page 15
Rapid Micro Biosystems 15 Distribution & Collaboration Partnership with Merck KGaA1(MilliporeSigma) Rapid Micro Biosystems© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.Advances and accelerates top strategic prioritiesAccelerating Growth Direct system placementsExpanding gross marginsDriving innovation •Global, 5-year, co-exclusive right to sell Growth Direct systems & consumables•Minimum commitment for Growth Direct system purchases in each of the first two years• Leverage MilliporeSigma’s extensive salesforce to deepen penetration in core pharma market worldwide• Access to segments beyond pharma including personal care, medical device, cosmetics and food & beverage• Collaboration on Supply Agreement to drive efficiencies, reduce product costs & accelerate gross margin expansion• Collaboration on Joint Product / Technology Innovation Partnership Highlights 1 The Life Science business of Merck KGaA, Darmstadt, Germany, operating in the U.S. as MilliporeSigma
Page 16
Rapid Micro Biosystems 2022 2023 2024 2025 2026e 2027e 2028e 2029e 2030e$37 - $41M (1)$17MDelivering consistent 20%+ revenue growth 16 R E V E N U E © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.(1) 2026 revenue guidance range reaffirmed on August 7, 2026Potential Revenue Growth Drivers• Scale existing Top 20 pharma customers through site and application expansion• Win new Top 20 and core pharma customers• Expand new products / services• Meaningful MilliporeSigma contribution across core and adjacent markets beginning in 2026• Leverage global automation standardization• Capture U.S. reshoring & capacity build-outRecurringNon-recurringNote: Data for 2026 – 2030 represents estimated future revenue based on current expectations, actual results may differ
Page 17
Rapid Micro Biosystems Significant progress and clear path to potential 50%+ gross margin 17 G R O S S M AR G I N % © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.(1) 2025 Gross Margin is adjusted to remove the impact of the one-time inventory write-down recorded in Q4 2025. See Rapid Micro Biosystems earnings release dated March 12, 2026 for reconciliation of total gross margin to Non-GAAP adjusted total gross margin.(2) 2026 Gross Margin reaffirmed on August 7, 2026.(50%)2022 Actual 2025 Actual 2026 Guidance 2028 Goal6% (1)~20% (50%)50%+ (exit)Expected primary drivers of 2026 Improvement•Systems: Material cost reduction, volume leverage•Consumables:Material cost reduction, volume leverage•Service:Higher productivity and lower per-unit service costs 56 percentage point improvement (actual)0%(50%) 50%Contribution to overall improvementConsumablesServiceSystemsNote: Data for 2026 – 2028 represents estimated future gross margin percentage based on current expectations, actual results may differ
Page 18
Rapid Micro Biosystems18 Growth Direct®is theindustry-leading platformChosen by 75% ofthe top 20 global pharma companies(1)with significant commercial runwayOperating behindstrong barriers to entryFirst mover advantage,little competition & robustpatent portfolioEnabling advanced pharmaceutical manufacturingGrowth Direct systems placed with 86% of approved CAR-T manufacturersAn expanding$10B+ marketDominated by manual,legacy processes that face increasing FDA scrutinyAttractive,high-growthbusiness modelDriving high-yieldrecurring revenue Rapid Micro Biosystems Creating the future of rapid, secure MQC automationto drive sustainable, long-term growth and shareholder value (1) By revenue© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.18
Page 19
Rapid Micro Biosystems Thank you© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.